Suppr超能文献

放射肿瘤学家和泌尿科医生是否认可主动监测低危前列腺癌的决策辅助工具:一项全国性调查的结果。

Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer: Results from a national survey.

机构信息

Northeast Ohio Medical University, Canal Fulton, OH, USA.

Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

Eur J Cancer Care (Engl). 2021 Jan;30(1):e13301. doi: 10.1111/ecc.13301. Epub 2020 Oct 27.

Abstract

OBJECTIVE

The degree decision aids (DAs) can promote active surveillance (AS) for prostate cancer (PCa) remains poorly understood. Herein, we surveyed radiation oncologists (RO) and urologists (URO) about their attitudes towards DAs in counselling patients about AS for low-risk PCa.

METHODS

We conducted a national survey of RO (n = 915) and URO (n = 940) to assess their attitudes about DAs for AS for patients with low-risk PCa. Respondents were queried about their attitudes towards DAs and proportion of PCa patients managed with AS. Multivariable logistic regression models were used to examine physician characteristics related to attitudes about DAs.

RESULTS

The overall response rate was 37.3% (n = 691). Most respondents strongly agreed or agreed that DAs helped patients with low-risk PCa make informed decisions (93.9%) and also increased patient support for AS (86.6%). Having a high volume of their low-risk PCa patients on AS (>15%) was associated with endorsing the statement that use of DAs increased the likelihood of recommending AS (OR: 1.83; 95% CI: 1.00-4.61; p = .05) and being a URO versus a RO (OR: 3.37; 95% CI: 2.46-5.79; p < .001).

CONCLUSIONS

Most specialists view DAs as effective tools to facilitate more informed treatment decisions and facilitate greater use of AS in appropriately selected patients.

摘要

目的

程度决策辅助工具(DA)可以促进前列腺癌(PCa)的主动监测(AS),但这一点仍知之甚少。在此,我们调查了放射肿瘤学家(RO)和泌尿科医生(URO)对 DA 在为低危 PCa 患者提供 AS 咨询方面的态度。

方法

我们对 RO(n=915)和 URO(n=940)进行了一项全国性调查,以评估他们对低危 PCa 患者 AS 的 DA 态度。受访者被询问他们对 DA 的态度以及接受 AS 管理的 PCa 患者比例。使用多变量逻辑回归模型来检查与 DA 态度相关的医生特征。

结果

总体回复率为 37.3%(n=691)。大多数受访者强烈同意或同意 DA 有助于低危 PCa 患者做出知情决策(93.9%),并增加了患者对 AS 的支持(86.6%)。有大量低危 PCa 患者接受 AS(>15%)与认可 DA 使用增加推荐 AS 的可能性相关(OR:1.83;95%CI:1.00-4.61;p=0.05)和 URO 与 RO 相比(OR:3.37;95%CI:2.46-5.79;p<0.001)。

结论

大多数专家认为 DA 是促进更知情治疗决策和促进适当选择患者更广泛使用 AS 的有效工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验